Cullinan Therapeutics, Inc. (CGEM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$75.1M
Cash & Equivalents
$46.1M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$1,114M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase1 Readout | — |
| 2026-11-01 | Phase1 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2027-01-01 | Phase1 Readout | — |
| 2027-02-27 | Pdufa | — |
Active Clinical Trials (8)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | PHASE2 | Active Not Recruiting | 284 |
| NCT06994143 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | PHASE1 | Recruiting | 37 |
| NCT07041099 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | PHASE1 | Recruiting | 36 |
| NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythema... | PHASE1 | Recruiting | 24 |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | PHASE1 | Active Not Recruiting | 30 |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | PHASE1 | Active Not Recruiting | 440 |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | PHASE1 | Recruiting | 60 |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | PHASE1 | Active Not Recruiting | 90 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.